Comparative renal, hepatic, and bone marrow toxicity of cisplatin and radioactive cisplatin (191Pt) in Wistar rats

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 5, 2006, Pages 528-534

  Norrgren, Kristina ^a   Sjölin, Maria ^a   Björkman, Sven ^a   Areberg, Johan ^a   Johnsson, Anders ^a   Johansson, L ^a   Mattsson, Sören ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cisplatin; Pt 191; Radioactive cisplatin; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CISPLATIN DERIVATIVE; CREATININE; CYTOTOXIC AGENT; PLATINUM 191; RADIOACTIVE MATERIAL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BONE MARROW TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE COUNT; WEIGHT GAIN;

ANIMALS; BONE MARROW DISEASES; CISPLATIN; FEMALE; KIDNEY DISEASES; LIVER DISEASES; PLATINUM; RADIOISOTOPES; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 33750995299     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.528     Document Type: Article

References (13)

1. Chenoufi N, Raoul JL, Lescout G, et al. In vitro demonstration of synergy between rudionuclide and chemotherapy. J Nucl Med 1998;39:900.
2. 191Pt-labeled cisplatin to a human cervical carcinoma cell line (ME-180). Int J Radiat Oncol Biol Phys 2000;46:1275.
3. Howell RW, Sastry SR. Cisplatinum-193m: Its microdosimetry and potential for chemo-Auger combination therapy of cancer. In: Schlafke-Stelson AT, Watson EE, eds, Proceedings of Fourth International Radiopharmaceutical Dosimetry Symposium, National Technical Information Service. Springfield, TN: Oak Ridge Associated Universities, 1986:493.
4. 191Pt) on nude mice. Int J Radiat Oncol Biol Phys 2001;49:827.
5. Brown E, Firestone RB. In: Shirley VS, ed, Table of radioactive isotopes. New York: Wiley/Interscience Publication. 1986.
6. 195mPt-labeled antitumor drug, cis-dichlorodiammineplatinum (II), cis-DDP*. Radiochimica Acta 1982;31:27.
7. 191pt-cisplatin. Acta Oncol 1999;38:221.
8. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988;21(2):163.
9. Johnsson A, Hoglund P, Grubb A, et al. Cisplatin pharmacokinetics and phannacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemother Pharmacol 1996;39 (1-2):25.
10. Johnsson A, Olsson C, Nygren O, et al. Pharmacokinetics and tissue distribution of cisplatin in nude mice: Platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 1995;37(1-2):23.
11. Bernhardt P, Benjegård SA, Kölby L, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Im J Radiat Oncol Biol Phys 2001;51(2):514.
12. Liberati T, Sansone SR, Feuston MH. Hematology and clinical chemistry values in pregnant Wistar Hannover rats compared with nonmated controls. Vet Clin Pathol 2004;33:68.
13. Sanderson JH, Phillips CE. An atlas of laboratory animal haematology. Oxford, United Kingdom: Clarendon Press, 1981.